I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 382.49 M, beating the estimate of USD 379.54 M.
EPS: As of FY2026 Q2, the actual value is USD 0.03, beating the estimate of USD -0.5185.
EBIT: As of FY2026 Q2, the actual value is USD 12.34 M.
Second Quarter 2026 Financial Highlights
Segment Revenue
Tempus AI, Inc.’s total revenue for the second quarter of 2026 was $382.5 million, representing a 22% year-over-year increase. For the six months ended June 30, 2026, total net revenue was $730.6 million, compared to $570.4 million for the same period in 2025.
Diagnostics revenue reached $289.3 million in Q2 2026, growing 20% year-over-year, primarily driven by Oncology volume growth of 31%. Hereditary revenue growth was 5%. For the six months ended June 30, 2026, Diagnostics revenue was $550.4 million, up from $435.6 million in 2025.
Data and Applications revenue was $93.2 million in Q2 2026, representing 28% year-over-year growth, with Insights revenue specifically growing 36%. For the six months ended June 30, 2026, Data and Applications revenue was $180.2 million, compared to $134.7 million in 2025.
Operational Metrics
Total gross profit increased 26% year-over-year to $246.5 million in Q2 2026. For the six months ended June 30, 2026, gross profit was $468.5 million, up from $350.2 million in 2025. Diagnostics gross profit was $181.1 million in Q2 2026, up from $142.1 million in Q2 2025. For the six months ended June 30, 2026, Diagnostics gross profit was $341.2 million, compared to $251.1 million in 2025. Data and Applications gross profit was $65.4 million in Q2 2026, up from $53.0 million in Q2 2025. For the six months ended June 30, 2026, Data and Applications gross profit was $127.3 million, compared to $99.1 million in 2025.
Loss from operations was - $75.9 million in Q2 2026, compared to - $61.8 million in Q2 2025. For the six months ended June 30, 2026, loss from operations was - $160.6 million, compared to - $130.5 million in 2025.
Net income was $5.6 million in Q2 2026, a significant improvement from a net loss of - $42.8 million in Q2 2025. For the six months ended June 30, 2026, net loss was - $120.3 million, compared to - $110.9 million in 2025.
Adjusted EBITDA was $8.0 million in Q2 2026, compared to - $5.6 million in Q2 2025. For the six months ended June 30, 2026, Adjusted EBITDA was $5.2 million, compared to - $21.8 million in 2025.
Total cost and operating expenses were $458.4 million in Q2 2026, compared to $376.4 million in Q2 2025. For the six months ended June 30, 2026, total cost and operating expenses were $891.2 million, compared to $700.8 million in 2025. Cost of revenues for diagnostics was $108.2 million in Q2 2026, up from $99.8 million in Q2 2025, and $209.2 million for the six months ended June 30, 2026, compared to $184.5 million in 2025. Cost of revenues for data and applications was $27.8 million in Q2 2026, up from $19.8 million in Q2 2025, and $52.9 million for the six months ended June 30, 2026, compared to $35.6 million in 2025. Technology research and development expenses were $43.9 million in Q2 2026, up from $34.5 million in Q2 2025, and $89.9 million for the six months ended June 30, 2026, compared to $67.9 million in 2025. Research and development expenses were $52.6 million in Q2 2026, up from $41.6 million in Q2 2025, and $100.9 million for the six months ended June 30, 2026, compared to $77.5 million in 2025. Selling, general and administrative expenses were $225.8 million in Q2 2026, up from $180.7 million in Q2 2025, and $438.4 million for the six months ended June 30, 2026, compared to $335.3 million in 2025.
Cash Flow
Cash and marketable securities totaled $820.7 million as of June 30, 2026. Cash and cash equivalents were $599.6 million as of June 30, 2026, compared to $604.8 million as of December 31, 2025. Marketable equity securities were $216.4 million as of June 30, 2026, up from $150.2 million as of December 31, 2025.
Net cash used in operating activities for the six months ended June 30, 2026, was - $80.8 million, compared to - $61.5 million for the same period in 2025. Net cash used in investing activities for the six months ended June 30, 2026, was - $21.2 million, compared to - $385.3 million for the same period in 2025. Net cash provided by financing activities for the six months ended June 30, 2026, was $96.9 million, compared to $293.0 million for the same period in 2025.
Unique Metrics
Molecular residual disease (MRD) volume was 9,000 tests in Q2 2026, an increase from 6,500 tests in the prior quarter. Tempus AI, Inc. signed approximately $200 million in new Data and Applications licenses during Q2 2026. The company also completed a $460 million offering of 0.0% convertible senior notes due 2032.
Outlook and Guidance
Tempus AI, Inc. is increasing its full year 2026 revenue guidance to $1.595 billion to $1.605 billion, representing approximately 25% annual growth. The company continues to expect full year 2026 Adjusted EBITDA to be approximately $65 million. This guidance assumes no impact from the pending acquisition of Personalis, which is expected to close in late Q4 2026 or early 2027.